Ambu A/S (CPH:AMBU.B)

Revenue

Financials in millions DKK. Fiscal year is October - September.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Mar 31, 2026	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020	Sep 30, 2019	Sep 30, 2018	Sep 30, 2017	Sep 30, 2016	Sep 30, 2015	Sep 30, 2014	Sep 30, 2013	Sep 30, 2012
Respiratory Revenue	1.87B	1.82B	1.65B
Respiratory Revenue Growth	2.58%	10.52%	10.63%
Urology (URO), Ear-Nose-Throat (ENT), and Gastroenterology (GI) Revenue	1.92B	1.83B	1.55B
Urology (URO), Ear-Nose-Throat (ENT), and Gastroenterology (GI) Revenue Growth	5.26%	18.19%	28.75%
Endoscopy Solutions Revenue	3.79B	3.64B	3.19B
Endoscopy Solutions Revenue Growth	3.92%	14.23%	18.72%
Anesthesia Revenue	1.19B	1.25B	1.16B
Anesthesia Revenue Growth	-4.64%	8.14%	5.67%
Patient Monitoring Revenue	1.13B	1.14B	1.05B
Patient Monitoring Revenue Growth	-1.57%	9.37%	5.13%
Anesthesia and Patient Monitoring Revenue	2.32B	2.39B	2.20B
Anesthesia and Patient Monitoring Revenue Growth	-3.18%	8.72%	5.41%
Revenue (Total)	6.10B	6.04B	5.39B
Revenue (Total) Growth	1.11%	11.98%	12.90%

Revenue by Geography

Financials in millions DKK. Fiscal year is October - September.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Mar 31, 2026	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020	Sep 30, 2019	Sep 30, 2018	Sep 30, 2017	Sep 30, 2016	Sep 30, 2015	Sep 30, 2014	Sep 30, 2013	Sep 30, 2012
North America Revenue	3.03B	3.05B	2.73B
North America Revenue Growth	-0.82%	11.68%	12.71%
Europe Revenue	2.51B	2.41B	2.11B
Europe Revenue Growth	4.16%	13.76%	13.47%
Rest of World Revenue	573.00M	581.00M	545.00M
Rest of World Revenue Growth	-1.38%	6.61%	11.68%
Revenue (Total)	6.10B	6.04B	5.39B
Revenue (Total) Growth	1.11%	11.98%	12.90%

Key Performance Indicators

Financials in millions DKK. Fiscal year is October - September.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016	FY 2015	FY 2014	FY 2013	FY 2012
Period Ending	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021	Sep 30, 2020	Sep 30, 2019	Sep 30, 2018	Sep 30, 2017	Sep 30, 2016	Sep 30, 2015	Sep 30, 2014	Sep 30, 2013	Sep 30, 2012
Respiratory - Organic Revenue Growth	11.40%	11.70%
Urology (URO), Ear-Nose-Throat (ENT), and Gastroenterology (GI) - Organic Revenue Growth	19.60%	29.60%
Endoscopy Solutions - Organic Revenue Growth	15.40%	19.70%
Anesthesia - Organic Revenue Growth	9.60%	6.70%
Patient Monitoring - Organic Revenue Growth	10.20%	5.50%
Anesthesia and Patient Monitoring - Organic Revenue Growth	9.90%	6.10%
Total Organic Revenue Growth	13.10%	13.80%
North America - Organic Revenue Growth	13.80%	14.30%
Europe - Organic Revenue Growth	13.30%	13.00%
Rest of World - Organic Revenue Growth	9.20%	14.20%

Data Source: Fiscal.ai Last updated: May 6, 2026

Financial data is provided by Fiscal.ai and updates within minutes after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 17, 2026

Data Sources Report a data error